跳至主要内容

Nonclinical Data Exchange Standard

 


1 Introduction

The purpose of this standard is to specify the format, content and method of exchange of non-clinical data to ensure data sharing and collaboration between different organizations. This standard applies to non-clinical data exchange involving drug development, approval and supervision.

2. Terms and Definitions

2.1 Non-clinical data: refers to data generated in the process of drug development, approval and supervision, but not used in clinical trials, including but not limited to data on pharmacodynamics, pharmacokinetics, toxicology, quality control, etc.

2.2 Data exchange: refers to the activities of sharing and obtaining non-clinical data between different organizations.

3. Non-clinical data exchange standards

3.1 Data format: Non-clinical data should adopt common data formats, such as CSV, Excel, JSON, etc., to ensure the readability and parsability of the data.

3.2 Data content: Non-clinical data should include the following:

3.2.1 Test names and identifiers: Specify the name, number, and other identifiers for each test.

3.2.2 Experimental design: Describe key information such as the experimental design plan, experimental animal species, administration route, dosage, etc.

3.2.3 Test results: Provide test results on pharmacodynamics, pharmacokinetics, toxicology, etc., including charts, statistical data, etc.

3.2.4 Data analysis: Preliminary analysis and interpretation of the test results, including the reliability, consistency and processing of outliers of the data.

3.2.5 Quality standards: Provide test-related quality standards, such as the health status of experimental animals, concentration and stability of dosing solutions, etc.

3.3 Data exchange method: Non-clinical data exchange should use secure electronic transmission methods, such as FTP, SFTP, HTTPS, etc., to ensure the confidentiality, integrity and availability of data.

4. Non-clinical data exchange process

4.1 The data provider and recipient should reach a data exchange agreement to clarify the scope, purpose and responsibilities of data sharing.

4.2 The data provider should send non-clinical data to the recipient in accordance with the specified data format and content.

4.3 After receiving the data, the recipient should verify and verify the data to ensure the integrity and accuracy of the data. If necessary, the provider can be asked to supplement or correct data.

4.4 The receiving party shall use non-clinical data in accordance with the purpose and scope of use specified in the agreement, and take necessary confidentiality measures.

5. Documentation and management

5.1 Non-clinical data exchange activities should be documented, including data exchange protocols, data sending and receiving records, etc.

5.2 Document records should be saved and managed in accordance with regulatory requirements to ensure traceability and accessibility of records.

6. Standardized reference guides and best practice recommendations refer to the guidelines and specifications issued by relevant international and national drug regulatory agencies, as well as best practice recommendations issued by industry associations, to ensure standardization and compliance of non-clinical data exchange.

评论

此博客中的热门博文

In Vitro Enzyme Activity Assay

  Kinases play extensive and important roles in signal transduction and co-ordination of complex functions. Currently, about 300 kinase inhibitors have been approved for marketing, among which receptor tyrosine kinase (RTK) inhibitors are the main ones. Medicilon provides high-quality kinase profile screening and has one-stop kinase research services from assay development, high-throughput screening to selectivity analysis. In addition, Medicilon provides many other enzyme activity screens. Wide Variety Provides 200+  in vitro  enzymatic detection methods; 100+ kinases, including CTK, RTK, AGC, CMGC and other kinase families as well as important common mutations Project Flexibility Various types of plates for screening, such as 96 and 384; Multiple flexible kinase profiles, including TK kinase family, CDK kinase family, etc., to meet different customer customization needs. Various Methods Fluorescence detection; Chemiluminescence detection; Absorbance detection LanthaScr...

Custom Synthesis

Medicilon has synthesized over 10,000 individual compounds from gram to kilogram quantities, and many compounds are synthesized with more than ten synthetic steps. The overall synthesis success rate is over 95%. High quality products from mg to kg scale Reagents, intermediates, building blocks, and scaffolds Preparation of API or reference standards Development of synthetic routes for impurities and metabolites   On-site analytical support Product delivered with COA Medicilon offers integrated drug discovery services -- Chemistry, Biology & Preclinical Services

Pharmacokinetics Services

Pharmacokinetics Services Our pharmacokinetics department offers the clients a broad spectrum of high quality of services in the areas of in vitro ADME, in vivo pharmacokinetics and bioanalysis services, ranging from small molecules to large molecules, such as protein and antibody. The animal species involved in our services are non-human primate, canine, mice, rat, rabbit and hamster. Meanwhile, non-human primate experimental platform and isotope platform for protein/antibody are certified by the Shanghai government. Preclinical Pharmacokinetics Method development and validation (GLP,Non-GLP) Bioanalysis Pharmacokinetics (Tumor bearing rodents, Bioavailability, Crossover studies, Cassette (N in 1) dosing and analysis, effects of gender on pharmacokinetics, BBB penetration ) Stability in vehicles and plasma Drug interaction studies In vitro metabolic stability CYP 450 inhibition Plasma protein binding studies Distribution studies Excretion studies Prediction an...